{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"groups":[{"description":"doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.\n\ngemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle","id":"OG000","title":"Gemcitabine+Doxorubicin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who were treated on study and had greater than grade 2 toxicity.","reportingStatus":"POSTED","timeFrame":"from time of initial treatment until end of study, an average of 6 months","title":"Number of Patients Who Had Greater Than Grade 2 Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}